Baillie Gifford & CO Rubius Therapeutics, Inc. Transaction History

Baillie Gifford & CO

$126 Billion
Q2 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 24, 2023	BUY	$0.14 - $0.31 $2,149 - $4,759	15,353 Added 0.32%	4,869,126 $838,000
Q3 2022 Oct 27, 2022	SELL	$0.46 - $1.29 $24,060 - $67,473	-52,305 Reduced 1.07%	4,853,773 $2.11 Million
Q2 2022 Aug 08, 2022	SELL	$0.79 - $5.98 $1,100 - $8,330	-1,393 Reduced 0.03%	4,906,078 $4.17 Million
Q1 2022 May 05, 2022	SELL	$4.25 - $10.4 $99,399 - $243,235	-23,388 Reduced 0.47%	4,907,471 $27 Million
Q4 2021 Jan 20, 2022	BUY	$9.68 - $17.74 $2.29 Million - $4.2 Million	237,027 Added 5.05%	4,930,859 $47.7 Million
Q3 2021 Oct 19, 2021	SELL	$17.6 - $25.91 $20,944 - $30,832	-1,190 Reduced 0.03%	4,693,832 $83.9 Million
Q2 2021 Aug 02, 2021	BUY	$22.26 - $28.43 $25,621 - $32,722	1,151 Added 0.02%	4,695,022 $115 Million
Q1 2021 May 06, 2021	SELL	$8.02 - $32.01 $129,843 - $518,241	-16,190 Reduced 0.34%	4,693,871 $124 Million
Q4 2020 Feb 10, 2021	BUY	$4.23 - $8.73 $1.85 Million - $3.81 Million	436,200 Added 10.21%	4,710,061 $35.7 Million
Q3 2020 Nov 12, 2020	BUY	$4.65 - $6.25 $88,949 - $119,556	19,129 Added 0.45%	4,273,861 $21.4 Million
Q2 2020 Aug 12, 2020	SELL	$4.01 - $6.88 $8,693 - $14,915	-2,168 Reduced 0.05%	4,254,732 $25.4 Million
Q1 2020 May 08, 2020	BUY	$3.74 - $9.84 $20,308 - $53,431	5,430 Added 0.13%	4,256,900 $18.9 Million
Q4 2019 Feb 10, 2020	BUY	$7.23 - $14.12 $77,382 - $151,126	10,703 Added 0.25%	4,251,470 $40.4 Million
Q3 2019 Nov 07, 2019	BUY	$7.85 - $15.75 $47,767 - $95,838	6,085 Added 0.14%	4,240,767 $33.3 Million
Q2 2019 Aug 08, 2019	BUY	$13.5 - $19.94 $1.37 Million - $2.03 Million	101,831 Added 2.46%	4,234,682 $66.6 Million
Q1 2019 May 01, 2019	BUY	$13.27 - $18.51 $1.02 Million - $1.42 Million	76,655 Added 1.89%	4,132,851 $0
Q4 2018 Feb 14, 2019	BUY	$13.83 - $22.97 $2.03 Million - $3.37 Million	146,584 Added 3.75%	4,056,196 $65.2 Million
Q3 2018 Nov 13, 2018	BUY	$20.06 - $26.94 $78.4 Million - $105 Million	3,909,612 New	3,909,612 $93.8 Million

Others Institutions Holding RUBY

# of Institutions

Shares Held

325

Call Options Held

Put Options Held

American Portfolios Advisors Holbrook, NY

325
Shares

$0
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Rubius Therapeutics, Inc.

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

More about RUBY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account